Clinical trials: Menopausal
Vaginitis, Atrophic Vaginitis
a Flexible Wound Dressing for the Management of Genital Skin Conditions
The objective of the study is to determine the efficacy of 7-0940 in the management of genital skin conditions in female patients
- Conditions
- Vaginitis, Atrophic Vaginitis, Lichen Planus, Lichen Sclerosus
- Trial name
- NCT05396261
- Testing
- Film forming silicone gel (7-0940)
- Where
- Australia
- Volunteers
- 54 people
- Sponsor
- Stratpharma AG
Fracture Healing
A Phase IIa Study Of Men And Post-Menopausal Women With A Fractured Distal Radius
This is a study designed to test the safety and effectiveness of SB-751689 in the treatment of a distal radius fracture in post-menopausal women and men in comparison to placebo to determine if healing time of the fracture can be…
- Trial name
- NCT00548496
- Testing
- SB-751689
- Where
- 37 sites in Argentina, Australia and 11 more
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Hot Flushes
E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)
This dose-finding study is being conducted to select the daily oral dose of estetrol (E4) for the treatment of vasomotor symptoms (VMS) in post-menopausal women.
- Trial name
- NCT02834312
- Testing
- Estetrol
- Where
- Belgium
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Donesta Bioscience
Ovarian Cancer
Optimal Timing of BR55 CEUS of the Ovaries
This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 contrast-enhanced ultrasonography (CEUS) of the target ovary in premenopausal…
- Trial name
- NCT04248153
- Testing
- BR55
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Bracco Diagnostics, Inc
Hypoactive Sexual Desire Disorder
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
This study is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of LibiGel® 300mcg in the treatment of HSDD in surgically menopausal women
- Trial name
- BLOOM (NCT00613002)
- Testing
- testosterone gel
- Where
- 63 sites in United States, Canada
- Volunteers
- 597 people
- Sponsor
- BioSante Pharmaceuticals
Diabetes Mellitus, Type 2
C-Reactive Protein (CRP) in Obese Diabetic Women
The purpose of this study is to determine whether treatment with rosuvastatin for 6 months in obese type 2 diabetic women will improve their lipid profiles and thus prevent the progression to cardiovascular disease.
- Trial name
- NCT00262548
- Testing
- Rosuvastatin; improvement of lipid profile
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Osteoporosis, Post-Menopausal
Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
The purpose of this study is to measure carotid artery IMT at a single visit in a subset of women previously enrolled in the CORE (H3S-MC-GGJY) trial
- Trial name
- NCT00532246
- Testing
- raloxifene
- Where
- 5 sites in United States
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Menopause, Climacteric Syndrome
Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
The study collected retrospective data from the assumption of combined natural molecules in menopausal women with metabolic syndrome
- Conditions
- Menopause, Climacteric Syndrome, Metabolic Syndrome
- Trial name
- NCT06057896
- Testing
- inositol, phytoestrogens, cocoa polyphenols
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Lo.Li.Pharma s.r.l
Vulvar Atrophy, Vulvovaginal Signs and Symptoms
Retrospective Cohort Study of Symptoms and Quality of Life in Women With Genitourinary Syndrome of Menopause.
The goal of this clinical trial is to retrospectively identify the most prevalent symptoms of genitourinary syndrome of menopause (GSM) among postmenopausal women and to evaluate their impact on quality of life.
- Conditions
- Vulvar Atrophy, Vulvovaginal Signs and Symptoms, Genitourinary Syndrome of Menopause (GSM), Quality of Life
- Trial name
- NCT07737782
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Mucosa Innovations, S.L.
Skin Aging, Reproductive Aging
Multidimensional Correlation Study on Skin Aging in Menopausal Women
Primary Objective: This study primarily aims to compare skin aging characteristics between women at different stages of reproductive aging in both sun-exposed and non-exposed areas, based on skin indicators collected during a…
- Conditions
- Skin Aging, Reproductive Aging, Menopause, Genetic Factors
- Trial name
- NCT07390305
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- ChinaNorm
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Although randomized controlled trials (RCTs) provide evidence of efficacy, generalization of these results to patients in the real-world setting is challenging, given RCTs are conducted in highly selected patient populations.
- Trial name
- Treat ER+ight (NCT02753686)
- Testing
- Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
- Where
- 25 sites in Canada
- Volunteers
- 440 people
- Sponsor
- Novartis Pharmaceuticals
Atrophy, Vaginal Diseases
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus
The primary objective of the study was to assess the long-term safety of 30- and 60-mg daily doses of ospemifene in the treatment of Vulvar and Vaginal Atrophy (VVA) in postmenopausal women with an intact uterus.
- Trial name
- NCT01585558
- Testing
- Ospemifene (Dose 1), Ospemifene (Dose 2)
- Volunteers
- 180 people
- Sponsor
- Shionogi
Healthy
Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions
The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the…
- Trial name
- NCT01181726
- Testing
- Estradiol/Norethindrone acetate, Activella®
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Postmenopausal Syndrome
Ex Vivo High-Throughput Assay for Vaginal Community Post-menopausal Women
This purpose of this study is to collect vaginal microbial samples of postmenopausal women to assess the optimal conditions for cultivation and storage of the vaginal microbiota.
- Trial name
- FLORA (NCT02415868)
- Where
- Netherlands
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Kimberly-Clark Corporation
Menopause
Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).
The study has been designed to look at the transfer from using LNG IUS for contraception only, in reproductive age to using it for endometrial protection in menopausal age.
- Trial name
- NCT00185458
- Testing
- LNG IUS
- Where
- 12 sites in Belgium, Finland and 2 more
- Volunteers
- 394 people
- Sponsor
- Bayer
Postmenopausal Symptoms
Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy
This study is intended to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause.
- Trial name
- NCT00160173
- Testing
- Estrogel
- Where
- 109 sites in United States
- Volunteers
- 221 people
- Sponsor
- ASCEND Therapeutics
Menopause, Menopausal Vasomotor Symptoms
Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations
This trial is conducted in Europe. Postmenopausal women with moderate to severe hot flashes have been recruited into the trial. The earliest effect of ultra low dose HRT (hormone replacement therapy) on frequency and severity of…
- Trial name
- CHOICE (NCT00184795)
- Testing
- 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA), 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)
- Where
- 91 sites in Austria, Belgium and 8 more
- Volunteers
- 576 people
- Sponsor
- Novo Nordisk A/S
Atrophy, Vaginal Diseases
A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women
The purpose of the study is to assess the efficacy, safety and tolerability of Ospemifene 5 mg, 15 mg, and 30 mg in the treatment of VVA in postmenopausal women to find the minimum effective dose below the lowest dose of 30 mg…
- Trial name
- NCT00630539
- Testing
- Ospemifene 5 mg, Ospemifene 15 mg, Ospemifene 30 mg
- Volunteers
- 126 people
- Sponsor
- Shionogi
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
- Trial name
- NCT00338312
- Testing
- Testosterone Transdermal System
- Where
- United States
- Volunteers
- 610 people
- Sponsor
- Warner Chilcott
Vaginal Atrophy
Exploratory Study on Two Different Doses of VML-0001 on the Effects on Vaginal pH in Healthy Post-Menopausal Women
The study is designed to determine the effect on vaginal pH and the duration of action measured on the ability of the base formulation to reduce the vaginal pH
- Trial name
- NCT03770065
- Testing
- VML-0001
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Viramal Limited